Wall Street analysts forecast that Replimune Group Inc (NASDAQ:REPL) will announce ($0.35) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Replimune Group’s earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.33). The company is expected to issue its next quarterly earnings report on Thursday, May 9th.
On average, analysts expect that Replimune Group will report full year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.49) to ($1.13). For the next fiscal year, analysts expect that the firm will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.90) to ($1.48). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Replimune Group.
Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, February 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.24).
Several institutional investors have recently bought and sold shares of REPL. Bain Capital Life Sciences Investors LLC acquired a new position in shares of Replimune Group during the 3rd quarter worth $45,707,000. Redmile Group LLC acquired a new position in Replimune Group in the 3rd quarter worth about $35,307,000. Foresite Capital Management IV LLC acquired a new position in Replimune Group in the 3rd quarter worth about $19,797,000. Foresite Capital Management III LLC acquired a new position in Replimune Group in the 3rd quarter worth about $12,552,000. Finally, FMR LLC acquired a new position in Replimune Group in the 3rd quarter worth about $7,773,000. 57.38% of the stock is owned by institutional investors.
REPL opened at $15.22 on Friday. Replimune Group has a 52-week low of $8.88 and a 52-week high of $23.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 38.14 and a quick ratio of 38.14.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Read More: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.